One would imagine that a large percentage of newly diagnosed CML patients are intelligent enough, and certainly motivated enough, to do their own due diligence regarding the most effective treatment. I know that for myself or any family member that I would strongly advocate for the most effective treatment initially in order to avoid the potential for relapse which apparently is the case for all the current medications except ponatinib. Most doctors who have no fiduciary interest in any particular treatment will be susceptible to the pressure brought to bear by patients and other patient advocates once the word gets around which it will (if it hasnt already) in the relatively small cml community. I dont see this med staying as a second line treatment for very long if the strong numbers hold up in the current trial which they should.
News 
Market Data 
Discover 
AI
